Announcement • Jun 29

MiniMed Group, Inc. Announces Board and Committee Changes, Effective June 29, 2026

MiniMed Group, Inc. increased the size of the Board from nine to 11 and appointed David Endicott and Linnea Burman to serve as directors of the Board to fill the resulting vacancies, effective June 29, 2026. Mr. Endicott will serve as a class I director whose term expires at the 2026 annual meeting of stockholders and will be a member of the Board’s Compensation and Talent Committee. Mr. Endicott currently serves as Chief Executive Officer of Alcon, Inc. and has served as a member of Alcon’s board of directors since 2019. Prior to joining Alcon, Inc., Mr. Endicott held senior leadership roles at various healthcare organizations, including as Chief Executive Officer and Chief Operating Officer of Alcon Laboratories, Inc., President of Hospira Infusion Systems at Hospira, Inc., and various commercial and regional leadership roles at Allergan, Inc. Mr. Endicott holds an M.B.A. from the University of Southern California and a B.A. in Chemistry from Whitman College. The Board has determined that Mr. Endicott is independent in accordance with the rules of The Nasdaq Stock Market LLC, the Securities and Exchange Commission and MiniMed’s corporate governance guidelines. Ms. Burman will serve as a class II director whose term expires at the 2027 annual meeting of stockholders. Ms. Burman currently serves as Senior Vice President & President, Neurovascular at Medtronic plc. From May 2020 to May 2024, Ms. Burman served as Vice President & General Manager, Enabling Technologies: Cranial & Spinal Technologies at Medtronic. Prior to these roles, Ms. Burman held various leadership positions at Medtronic over a tenure spanning more than 19 years, including Vice President & General Manager, Pelvic Health & Gastric Therapies, Neurosciences Vice President of Strategic Planning & Communications, and Director of Marketing, US Pain Stimulation & Targeted Drug Delivery, as well as earlier marketing and market development roles. Ms. Burman holds a B.A. in Communication Studies, with an emphasis in Public Relations from Virginia Tech. David Endicott is a lifelong healthcare executive with leadership experience across global pharmaceutical and medical device companies. He currently serves as Chief Executive Officer of Alcon, an eye care company, and has served as a member of Alcon's board of directors since 2019. He joined Alcon in July 2016 as Chief Operating Officer, was named Chief Executive Officer in July 2018, and led Alcon's spin out and return to the public markets. Prior to joining Alcon, Endicott was President of Hospira Infusion Systems, a Pfizer company. Before joining Hospira, he served as an officer and executive committee member of Allergan, where he spent more than 25 years in leadership roles spanning the United States, Europe, Asia, and Latin America. Endicott previously served on the boards of directors of Zeltiq, Inc. and Orexigen Therapeutics, Inc., and currently serves on the board of AdvaMed. Linnea Burman is currently Senior Vice President and President, Neurovascular at Medtronic. Across more than 19 years at Medtronic, she has held a range of senior operating and strategic leadership roles, including Vice President and General Manager, Enabling Technologies, Cranial and Spinal Technologies, and Vice President and General Manager, Pelvic Health and Gastric Therapies.

MiniMed Group, Inc. Stock Price

MMED Share Price Performance

MMED Community Narratives

Trending Discussion

Recently Updated Narratives

Snowflake Analysis

MiniMed Group, Inc. Key Details

About MMED

Recent MMED News & Updates

MiniMed Flex Insulin Pump Now Reaches Medicare and Medicare Advantage Users

MiniMed Group, Inc., Annual General Meeting, Oct 09, 2026

MiniMed Group, Inc. Announces Board and Committee Changes, Effective June 29, 2026

Recent updates

MiniMed Group, Inc. Competitors

DexCom

Quest Diagnostics

Labcorp Holdings

STERIS